Showing results (1851-1860 of 3,353) with videos related to
Sort By:
Pageof 336
Pharmacoeconomics|October 28, 1999
A prospective cost-consequence analysis of adding lamivudine to zidovudine-containing antiretroviral treatment regimens for HIV infection in the USL Lacey, J Mauskopf, R Lindrooth, et al.Pharmacoeconomics|October 28, 1999
An evaluation of the cost effectiveness of adding lamivudine to zidovudine-containing regimens in HIV infection. Canadian perspectiveL Lacey, P K Hopkinson, J Montaner, et al.Pharmacoeconomics|October 28, 1999
Quality of life and treatment satisfaction after the addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens in treatment-experienced patients with HIV infectionM L Chatterton, J Scott-Lennox, A W Wu, et al.Pharmacoeconomics|October 28, 1999
Incremental cost-effectiveness analysis of intravenous ganciclovir versus oral ganciclovir in the maintenance treatment of newly diagnosed cytomegalovirus retinitis in patients with AIDSA Rachlis, F Smaill, V Walker, et al.Pharmacoeconomics|October 28, 1999
Donepezil. Pharmacoeconomic implications of therapyR H Foster, G L PloskerPharmacoeconomics|October 28, 1999
Cost effectiveness of riluzole in amyotrophic lateral sclerosis. Italian Cooperative Group for the Study of Meta-Analysis and the Osservatorio SIFO sui FarmaciA Messori, S Trippoli, P Becagli, et al.Pharmacoeconomics|October 28, 1999
The influence of hospital-based prescribers on prescribing in general practiceJ Feely, R Chan, J McManus, et al.Pharmacoeconomics|September 30, 2000
Health-related quality of life in asymptomatic patients with HIV. Evaluation of the SF-36 health survey in Italian patientsF Arpinelli, G Visonà, R Bruno, et al.Pharmacoeconomics|January 11, 2001
The distribution of sales revenues from pharmaceutical innovationH G Grabowski, J VernonPharmacoeconomics|January 11, 2001
Is there a link between pharmaceutical consumption and improved health in OECD countries?R D Miller, H E FrechPageof 336